---
title: "Emei Shan Tour released its performance for the first half of the year, with a net profit attributable to the parent company of 121 million yuan, a decrease of 8.48%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/251805989.md"
description: "According to the Zhitong Finance APP, Emei Shan Tour released its semi-annual report for 2025, reporting an operating income of 457 million yuan, a year-on-year decrease of 10.07%. The net profit attributable to shareholders of the listed company was 121 million yuan, a year-on-year decrease of 8.48%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 119 million yuan, a year-on-year decrease of 9.65%. The basic earnings per share were 0.2302 yuan"
datetime: "2025-08-06T10:09:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251805989.md)
  - [en](https://longbridge.com/en/news/251805989.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251805989.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/251805989.md) | [English](https://longbridge.com/en/news/251805989.md)


# Emei Shan Tour released its performance for the first half of the year, with a net profit attributable to the parent company of 121 million yuan, a decrease of 8.48%

According to the Zhitong Finance APP, Emei Shan Tour (000888.SZ) released its semi-annual report for 2025, reporting an operating income of 457 million yuan, a year-on-year decrease of 10.07%. The net profit attributable to shareholders of the listed company was 121 million yuan, a year-on-year decrease of 8.48%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 119 million yuan, a year-on-year decrease of 9.65%. The basic earnings per share were 0.2302 yuan

### 相關股票

- [Emei Shan Tour (000888.CN)](https://longbridge.com/zh-HK/quote/000888.CN.md)

## 相關資訊與研究

- [China AI giants offer better value than US peers, top fund says](https://longbridge.com/zh-HK/news/278962257.md)
- [Swire Pacific (SEHK:19) One Off HK$6.7b Loss Tests Bullish Earnings Growth Narrative](https://longbridge.com/zh-HK/news/279080849.md)
- [Tajikistan Approves Hebei Changsha Biochemical Pharmaceutical's Thrombosis Injection](https://longbridge.com/zh-HK/news/278372421.md)
- [Red Cross launches Iran emergency appeal as needs soar](https://longbridge.com/zh-HK/news/278534784.md)
- [AP Shills For Big Pharma Antidepressants With 'Bewildering' Hit Piece](https://longbridge.com/zh-HK/news/278620492.md)